Do analysts prefer ELYM or NBTX?

Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 6.67%. Given Nanobiotix's stronger consensus rating and higher probable upside, analysts clearly believe Nanobiotix is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nanobiotix 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation and earnings, ELYM or NBTX?

Nanobiotix has higher revenue and earnings than Eliem Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A Nanobiotix $36.87M 54.92 -$27.11M N/A N/A

Is ELYM or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Nanobiotix N/A N/A N/A

Do analysts recommend AGIO or ELYM?

Agios Pharmaceuticals presently has a consensus target price of $41.25, suggesting a potential upside of 24.51%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.55 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate TSHA or ELYM?

Taysha Gene Therapies currently has a consensus price target of $12.77, suggesting a potential upside of 129.25%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is TSHA or ELYM more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.19% -41.84% Eliem Therapeutics N/A -47.03% -45.97%

Do analysts recommend ELYM or SRPT?

Sarepta Therapeutics has a consensus target price of $25.06, suggesting a potential upside of 9.00%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sarepta Therapeutics 5 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is ELYM or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Eliem Therapeutics (ELYM) Competitors

$15.05 +0.23 (+1.55%)

As of 09/2/2026

Compare

ELYM vs. NBTX, AGIO, TSHA, SRPT, and LKFT

Should you buy Eliem Therapeutics stock or one of its competitors? Eliem Therapeutics's main competitors and comparable companies include Nanobiotix (NBTX), Agios Pharmaceuticals (AGIO), Taysha Gene Therapies (TSHA), Sarepta Therapeutics (SRPT), and Lakefront Biotherapeutics American Depositary Shares (LKFT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eliem Therapeutics compare to Nanobiotix?

Eliem Therapeutics (NASDAQ:ELYM) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Nanobiotix has higher revenue and earnings than Eliem Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Nanobiotix	$36.87M	54.92	-$27.11M	N/A	N/A

In the previous week, Nanobiotix had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Nanobiotix and 0 mentions for Eliem Therapeutics. Nanobiotix's average media sentiment score of 0.75 beat Eliem Therapeutics' score of 0.00 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Nanobiotix	Positive

Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 6.67%. Given Nanobiotix's stronger consensus rating and higher probable upside, analysts clearly believe Nanobiotix is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nanobiotix's return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Nanobiotix	N/A	N/A	N/A

Summary

Nanobiotix beats Eliem Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Eliem Therapeutics compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Eliem Therapeutics (NASDAQ:ELYM) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

69.8% of Eliem Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eliem Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Agios Pharmaceuticals presently has a consensus target price of $41.25, suggesting a potential upside of 24.51%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Agios Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market.

Eliem Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	36.61	-$412.78M	-$7.01	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, Agios Pharmaceuticals had 7 more articles in the media than Eliem Therapeutics. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 0 mentions for Eliem Therapeutics. Agios Pharmaceuticals' average media sentiment score of 1.43 beat Eliem Therapeutics' score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Agios Pharmaceuticals	Positive
Eliem Therapeutics	Neutral

Summary

Agios Pharmaceuticals beats Eliem Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Eliem Therapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Taysha Gene Therapies currently has a consensus price target of $12.77, suggesting a potential upside of 129.25%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

Eliem Therapeutics' return on equity of -47.03% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Eliem Therapeutics	N/A	-47.03%	-45.97%

In the previous week, Taysha Gene Therapies' average media sentiment score of 0.00 equaled Eliem Therapeutics'average media sentiment score.

Company	Overall Sentiment
Taysha Gene Therapies	Neutral
Eliem Therapeutics	Neutral

Eliem Therapeutics has lower revenue, but higher earnings than Taysha Gene Therapies. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	185.76	-$109M	-$0.42	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Summary

Taysha Gene Therapies beats Eliem Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Eliem Therapeutics compare to Sarepta Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Eliem Therapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

Sarepta Therapeutics has a consensus target price of $25.06, suggesting a potential upside of 9.00%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sarepta Therapeutics	5 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.20

Eliem Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Sarepta Therapeutics	$2.20B	1.10	-$713.41M	-$2.90	N/A

In the previous week, Sarepta Therapeutics had 14 more articles in the media than Eliem Therapeutics. MarketBeat recorded 14 mentions for Sarepta Therapeutics and 0 mentions for Eliem Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.07 beat Eliem Therapeutics' score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Sarepta Therapeutics	Positive

Summary

Sarepta Therapeutics beats Eliem Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Eliem Therapeutics (NASDAQ:ELYM) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $30.67, suggesting a potential upside of 5.67%. Given Lakefront Biotherapeutics American Depositary Shares' stronger consensus rating and higher probable upside, analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.52	$363.05M	-$1.41	N/A

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Lakefront Biotherapeutics American Depositary Shares and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 equaled Lakefront Biotherapeutics American Depositary Shares'average media sentiment score.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Lakefront Biotherapeutics American Depositary Shares	Neutral

Summary

Lakefront Biotherapeutics American Depositary Shares beats Eliem Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELYM vs. The Competition

Export

Metric	Eliem Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$447.77M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-28.40	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	3.86	16.29	12.89	6.14
Net Income	-$35.12M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-0.07%	0.34%	0.60%	-0.27%
1 Month Performance	27.43%	8.52%	5.73%	0.68%
1 Year Performance	516.80%	52.66%	25.35%	14.84%

Eliem Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELYM Eliem Therapeutics	N/A	$15.05 +1.6%	N/A	+574.9%	$447.77M	N/A	N/A	9	High Trading Volume
NBTX Nanobiotix	1.0981 of 5 stars	$44.50 +7.2%	$37.33 -16.1%	+362.7%	$2.10B	$36.87M	N/A	100
AGIO Agios Pharmaceuticals	2.6804 of 5 stars	$33.99 +0.3%	$41.25 +21.4%	-18.4%	$2.02B	$54.03M	N/A	390
TSHA Taysha Gene Therapies	2.1886 of 5 stars	$6.02 -2.9%	$12.77 +112.1%	+92.1%	$2.02B	$9.77M	N/A	180
SRPT Sarepta Therapeutics	2.4269 of 5 stars	$19.46 +2.9%	$25.06 +28.8%	+21.3%	$2.00B	$2.20B	N/A	1,372	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELYM) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eliem Therapeutics (ELYM) Competitors

ELYM vs. NBTX, AGIO, TSHA, SRPT, and LKFT

How does Eliem Therapeutics compare to Nanobiotix?

Summary

How does Eliem Therapeutics compare to Agios Pharmaceuticals?

Summary

How does Eliem Therapeutics compare to Taysha Gene Therapies?

Summary

How does Eliem Therapeutics compare to Sarepta Therapeutics?

Summary

How does Eliem Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eliem Therapeutics (ELYM) Competitors

ELYM vs. NBTX, AGIO, TSHA, SRPT, and LKFT

How does Eliem Therapeutics compare to Nanobiotix?

Which has stronger valuation and earnings, ELYM or NBTX?

Does the media refer more to ELYM or NBTX?

Do analysts prefer ELYM or NBTX?

Which has more risk & volatility, ELYM or NBTX?

Do insiders & institutionals have more ownership in ELYM or NBTX?

Is ELYM or NBTX more profitable?

Summary

How does Eliem Therapeutics compare to Agios Pharmaceuticals?

Do insiders and institutionals hold more shares of AGIO or ELYM?

Is AGIO or ELYM more profitable?

Do analysts recommend AGIO or ELYM?

Which has more risk & volatility, AGIO or ELYM?

Which has better earnings & valuation, AGIO or ELYM?

Does the media refer more to AGIO or ELYM?

Summary

How does Eliem Therapeutics compare to Taysha Gene Therapies?

Do insiders & institutionals hold more shares of TSHA or ELYM?

Do analysts rate TSHA or ELYM?

Which has more volatility and risk, TSHA or ELYM?

Is TSHA or ELYM more profitable?

Does the media favor TSHA or ELYM?

Which has better valuation and earnings, TSHA or ELYM?

Summary

How does Eliem Therapeutics compare to Sarepta Therapeutics?

Which has more volatility and risk, ELYM or SRPT?

Do institutionals and insiders hold more shares of ELYM or SRPT?

Is ELYM or SRPT more profitable?

Do analysts recommend ELYM or SRPT?

Which has preferable valuation and earnings, ELYM or SRPT?

Does the media refer more to ELYM or SRPT?

Summary

How does Eliem Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Do institutionals & insiders hold more shares of ELYM or LKFT?

Do analysts recommend ELYM or LKFT?

Which has more risk & volatility, ELYM or LKFT?

Which has stronger earnings & valuation, ELYM or LKFT?

Is ELYM or LKFT more profitable?

Does the media refer more to ELYM or LKFT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools